Weight loss drug Belviq has been linked to an increased risk of cancer
Ever since Belviq entered the market in the United States, and even before it was approved, there have been concerns about the potential for the drug to cause cancer and other serious problems in users. In fact, the release of Belviq was originally rejected in 2010 due to the fact that rodent testing had found a higher rate of brain and breast cancer associated with the weight loss drug. However, Arena Pharmaceuticals convinced federal regulators that the tumors found in the rats were specific to rodents and not likely to affect humans and the drug was approved for sale in the United States two years after the initial rejection. At that time, the FDA noted the following:
“When approving [Belviq], we required the drug manufacturer, Eisai Inc., to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. In this trial, which was conducted in approximately 12,000 participants over 5 years, more patients taking [Belviq] were diagnosed with cancer compared to patients taking placebo, which is an inactive treatment. Our evaluation of this potential signal is ongoing, and at this time it is uncertain if [Belviq] increases the risk of cancer.”
Despite years of growing concerns about the potential risk of cancer from Belviq treatment, it wasn’t until January 2020 that the FDA issued a drug safety communication warning that clinical trial data had shown a possible link between the use of Belviq and an increased risk of cancer. Based on this potential risk, the FDA advised healthcare providers to “consider if the benefits of taking lorcaserin are likely to exceed the potential risks when deciding whether to prescribe or continue patients on lorcaserin.”
Were you or a loved one diagnosed with cancer after using weight loss drug Belviq?
Find out if you qualify for compensation.Find Out More
Consumer Safety Watch offers safety advocate services and attorney referral services for patients throughout the United States including the states of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
Consumer Safety Watch offers consumer safety advocate services or can help you find an attorney throughout the United States including the following cities: Albuquerque, NM; Arlington, TX; Atlanta, GA; Austin, TX; Baltimore, MD; Boston, MA; Charlotte, NC; Chicago, IL; Cleveland, OH; Colorado Springs, CO; Columbus, OH; Dallas, TX; Denver, CO; Detroit, MI; Fresno, CA; Fort Worth, TX; Indianapolis, IN; Honolulu, HI; Houston, TX; Jacksonville, FL; Kansas City, KS; Kansas City, MO; Las Vegas, NV; Long Beach, CA; Los Angeles, CA; Louisville, KY; Memphis, TN; Mesa, AZ; Miami, FL; Miami, OH; Milwaukee, WI; Minneapolis, MN; Nashville, TN; New York City, NY; Oakland, CA; Oklahoma City, OK; Omaha, NE; Philadelphia, PA; Phoenix, AZ; Pittsburgh, PA; Portland, OR; Sacramento, CA; San Antonio, Tx; San Diego, CA; San Francisco, CA; San Jose, CA; Seattle, WA; St. Louis, MO; Tampa, FL; Tucson, AZ; Tulsa, Virginia Beach, VA; Washington, DC; Wichita, KS.
This website is not affiliated with any pharmaceutical or medical device company or any trademarked product. Results are not guaranteed. This website provides a free matching service and is not responsible for information or services from third party providers. Consumer Safety Watch is not a law firm. Every case is different and services available can vary.